EU Boosters: A Patchwork of Plans Before the EMA’s Verdict
Across Europe, governments are already humming a booster‑shot beat, even though the European Medicines Agency (EMA) still needs to give the green light. It’s a bit like a holiday parade where some countries are already on the dance floor while others are waiting to see if the music will sound right.
Some Countries Are Already Jumping In
- Italy – Targeting roughly 9 million people, including the immunocompromised, the elderly and frontline health workers.
- France, Germany, Ireland – These nations have begun their own booster campaigns, though they’re focusing mainly on vulnerable groups.
- Netherlands – A cautious approach: only about 400,000 immunosuppressed citizens are in line for a third jab, and it’s still up for debate whether anyone else should get one.
- Denmark – Plans to extend extra doses to medical staff and anyone over 65, pending EMA approval.
- Switzerland – For now, no boosters. The health folks aren’t convinced protection is slipping and are monitoring data closely.
The EMA Had Better Decide Fast
The regulator is expected to weigh in on Monday, yet it’s unlikely to hand out a detailed playbook on who exactly gets a booster. Meanwhile, the European Centre of Disease Prevention and Control (ECDC) is offering a thumbs‑up for extra doses for those with severely weakened immune systems, and maybe even for frail care‑home residents and exposed healthcare workers.
Still, both the EMA and ECDC agree we’re knee‑deep in a data crunch. The long‑term drop in protection and the battle against the Delta variant still need more robust evidence.
Vaccination Coverage: Room for Improvement
The EU’s infectious diseases hub admitted on Sept 30 that coverage is still shaky, with only 61 % of the population fully vaccinated. Three countries—Malta, Portugal, and Iceland—have exceeded 75 % coverage, but big gaps remain. Bulgaria, for instance, lacks 25 % of its people fully immunized.
Rich nations are now rummaging through boosters while poorer countries struggle to secure enough doses for their own citizens. The World Health Organization (WHO) has urged countries to hold off on additional shots until more people worldwide have a chance to get vaccinated.
What’s the Big Deal with the Pfizer Booster?
Results from Israel are driving the conversation. Over 1.1 million folks aged 60+ received a Pfizer booster, and it led to a noticeable dip in both infection rates and severe COVID cases among that age group. This data, combined with findings from Pfizer and Moderna’s own clinical trials, suggests that while initial protection was over 90 %, it fades over time.
Most experts say that the “booster” buzz is mainly for older adults and those with compromised immune systems. The community is still waiting to see whether a broader rollout is warranted.
Final Words: The Road Ahead
As EU nations toggle between cautious and proactive, the EMA’s decision will set the tone. If the regulator gives its nod, the bloc will align with the U.S., Britain, and Israel—already shooting boosters at a wide audience. Until then, the conversation continues: Will the extra dose be a rescue mission for the vulnerable, or a gamble that runs the risk of diverting supplies away from those still unvaccinated across the globe?
